COSENTYX (secukinumab), anti-interleukin-17A immunosuppressant
RHEUMATOLOGY - New indication
Opinions on drugs - Posted on Aug 23 2016
Reason for request
No clinical benefit demonstrated by comparison with anti-TNF therapy in the treatment of ankylosing spondylitis
- COSENTYX has Marketing Authorisation for the treatment of active ankylosing spondylitis in adults in case of inadequate response to conventional treatment.
- Given the lack of direct comparison of secukinumab to anti-TNF therapy and more significant long-term data with the latter, COSENTYX must be reserved as second line, after failure of anti-TNF therapy.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments